Titolo	Data di pubblicazione	Autore(i)
1	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia	2007	CILLONI D; MESSA F; MARTINELLI G; GOTTARDI E; ARRUGA F; DEFILIPPI I; CARTURAN; S; MESSA E; FAVA M; GIUGLIANO E; ROSSO V; CATALANO R; MERANTE S; NICOLI P; RONDONI M; OTTAVIANI E; SOVERINI S; TIRIBELLI M; PANE F; BACCARANI M; SAGLIO G
2	WT1 overexpression: A clinically useful marker in acute and chronic myeloid leukemias	2005	SAGLIO G; CARTURAN S; GRILLO S; CAPELLA S; ARRUGA F; DEFILIPPI I; ROSSO V; RAUCO M; MARINA LIBERATI A; CILLONI D
3	WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes.	2006	Cilloni D; Gottardi E; Saglio G.
4	WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome	2004	CILLONI D; SAGLIO G
5	Wilms’ tumour gene (WT1) is modulated by NF-kB transcriptional factor	2002	Messa F; Cilloni D; Fava M; Morotti A; Messa E; Gottardi E; Saglio G
6	The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy	2016	Gallo, Daniela; Nicoli, Paolo; Calabrese, Chiara; Gaidano, Valentina; Petiti, Jessica; Rosso, Valentina; Signorino, Elisabetta; Carturan, Sonia; Bot-Sartor, Giada; Volpe, Gisella; Frassoni, Francesco; Saglio, Giuseppe; Cilloni, Daniela
7	What challenges remain in chronic myeloid leukemia research?	2013	A. M. Carella;S. Branford;M. Deininger;F. X. Mahon;G. Saglio;A. Eiring;J. Khorashad;T. O'Hare;J. M. Goldman
8	What are RBC-transfusion-dependence and -independence?	2011	Gale RP; Barosi G; Barbui T; Cervantes F; Dohner K; Dupriez B; Gupta V; Harrison C; Hoffman R; Kiladjian JJ; Mesa R; Mc Mullin MF; Passamonti F; Ribrag V; Roboz G; Saglio G; Vannucchi A; Verstovsek S.
9	Very low doses of thalidomide as singleagent in relapsed/refractory multiple myeloma.	2006	Guglielmelli T; Capella S; Saglio G.
10	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response	2015	Iurlo, A; Latagliata, R; Bucelli, C; Ferrero, D; Castagnetti, F; Breccia, M; Abruzzese, E; Cattaneo, D; Fava, C; Gozzini, A; Annunziata, M; Tiribelli, M; Pregno, P; Stagno, F; Vigneri, P; Cavazzini, F; Binotto, G; Mansueto, G; Russo, S; Falzetti, F; Montefusco, E; Gugliotta, G; Gasbarrino, C; D'Addosio, A; Cortesi, L; Cedrone, M; Rossi, Ar; Avanzini, P; Endri, M; Spadea, A; Celesti, F; Giglio, G; Isidori, A; Crugnola, M; Calistri, E; Sora, F; Rege-Cambrin, G; Sica, S; Luciano, L; Orlandi, Em; Bocchia, M; Tettamanti, M; Alimena, G; Saglio, G; Rosti, G; Nobili, A; Mannucci, Pm; Cortelezzi, A
11	VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?	2015	Iurlo, A; Latagliata, R; Bucelli, C; Ferrero, D; Castagnetti, F; Breccia, M; Abruzzese, E; Fava, C; Annunziata, M; Stagno, F; Vigneri, P; Tiribelli, M; Cavazzini, F; Binotto, G; Mansueto, G; Gozzini, A; Russo, S; Falzetti, F; Montefusco, E; Gugliotta, G; Cattaneo, D; Djade, Cd; Cedrone, M; Rossi, Ar; Avanzini, P; Pregno, P; Mauro, E; Endri, M; Spadea, A; Celesti, F; Giglio, G; Isidori, A; Crugnola, M; Calistri, E; Sora, F; Sica, S; Storti, S; D'Addosio, A; Rege-Cambrin, G; Luciano, L; Saglio, G; Rosti, G; Alimena, G; Nobili, A; Cortelezzi, A
12	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis	2011	Marzocchi G; Castagnetti F; Luatti S; Baldazzi C; Stacchini M; Gugliotta G; Amabile M; Specchia G; Sessarego M; Giussani U; Valori L; Discepoli G; Montaldi A; Santoro A; Bonaldi L; Giudici G; Cianciulli AM; Giacobbi F; Palandri F; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G; Testoni N.
13	Variant breakpoint positions on chromosome 22 in Ph'-positive chronic myelogenous leukemias.	1989	GUERRASIO A ;ROSSO C ;TASSINARI A ;ZACCARIA A ;SAGLIO G
14	Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection	2016	Carturan, Sonia; Petiti, Jessica; Rosso, Valentina; Calabrese, Chiara; Signorino, Elisabetta; Bot Sartor, Giada; Nicoli, Paolo; Gallo, Daniela; Bracco, Enrico; Morotti, Alessandro; Panuzzo, Cristina; Gottardi, Enrico; Frassoni, Francesco; Saglio, Giuseppe; Cilloni, Daniela
15	Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies.	1988	SAGLIO G; A. GUERRASIO; TASSINARI A; PONZETTO C; ZACCARIA A; TESTONI P; CELSO B; REGE CAMBRIN G; SERRA A; PEGORARO L
16	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.	2006	Morotti A;Cilloni D;Messa F;Arruga F;Defilippi I;Carturan S;Catalano R;Rosso V;Chiarenza A;Pilatrino C;Guerrasio A;Taulli R;Bracco E;Pautasso M;Baraban D;Gottardi E;Saglio G
17	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leucemia cells	2006	MOROTTI A; CILLONI D; MESSA F; ARRUGA F; DEFILIPPI I; CARTURAN S; CATALANO; R; ROSSO V; CHIARENZA A; PILATRINO C; GUERRASIO A; TAULLI R; BRACCO E; PAUTASSO; M; BARABAN D; GOTTARDI E; SAGLIO G.
18	Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients	2004	CILLONI D; CARTURAN S; GOTTARDI E; MESSA F; FAVA M; DEFILIPPI I; ARRUGA F; SAGLIO G.
19	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy.	2003	D. CILLONI; SAGLIO G.
20	Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection	2003	CILLONI D; GOTTARDI E; FAVA M; MESSA F; CARTURAN S; BUSCA A; GUERRASIO A; G. SAGLIO